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Dr. Subotića 4, 11129 Belgrade, Serbia
Correspondence should be addressed to Juan F. Santibanez; jfsantibanez@imi.bg.ac.rs
Received 11 January 2015; Revised 20 March 2015; Accepted 13 April 2015
Academic Editor: Angel Catalá
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Transforming growth factor-beta (TGF-𝛽) and oxidative stress/ReactiveOxygen Species (ROS) both have pivotal roles in health and
disease. In this review we are analyzing the interplay between TGF-𝛽 and ROS in tumorigenesis and cancer progression.They have
contradictory roles in cancer progression since both can have antitumor effects, through the induction of cell death, senescence
and cell cycle arrest, and protumor effects by contributing to cancer cell spreading, proliferation, survival, and metastasis. TGF-𝛽
can control ROS production directly or by downregulating antioxidative systems. Meanwhile, ROS can influence TGF-𝛽 signaling
and increase its expression as well as its activation from the latent complex. This way, both are building a strong interplay which
can be taken as an advantage by cancer cells in order to increment their malignancy. In addition, both TGF-𝛽 and ROS are able to
induce cell senescence, which in one way protects damaged cells from neoplastic transformation but also may collaborate in cancer
progression.Themutual collaboration of TGF-𝛽 and ROS in tumorigenesis is highly complex, and, due to their differential roles in
tumor progression, careful consideration should be taken when thinking of combinatorial targeting in cancer therapies.
1. Introduction
Metastasis results from a complex molecular cascade which
allows cancer cells to gain malignancy and leave the primary
tumormass and disseminate to distant anatomical sites where
they can proliferate and form secondary tumor foci. Dissem-
inated disease is the most usual cause of death in cancer
patients and is, therefore, a very serious clinical problem [1].
Transforming growth factor-beta (TGF-𝛽) has been postu-
lated to have a dual role in tumor progression, acting as a
tumor suppressor in early stages of carcinogenesis and exert-
ing a prooncogenic role in the last steps of the metastatic dis-
ease [2]. TGF-𝛽 induces the epithelial mesenchymal transi-
tion (EMT) of transformed cells, which contributes to tumor
invasion and metastasis, and is frequently overexpressed in
carcinoma cells [3–7].
In normal physiological conditions, Reactive Oxygen
Species (ROS) producers constantly generate ROS, while they
are eliminated by ROS scavenging systems, thus maintaining
redox homeostasis. Redox imbalance, due to aberrant ROS
production and/or antioxidant functionality, contributes to
tumor progression and is a hallmark of several types of cancer
[8, 9]. ROS may participate in cancer initiation, progression,
and spreading acting as secondary messengers in the acti-
vation and maintenance of signaling pathways which regu-
late cellular proliferation, survival, angiogenesis, EMT, and
metastasis [9]. It is believed that ROS mediate many effects
of TGF-𝛽 during tumorigenesis, since they participate in the
regulation of downstream TGF-𝛽 signal transduction which
involves Smads, MAPKs, and NF-𝜅B, as well as the increase
of cell motility [10–12]. Meanwhile, TGF-𝛽 is able to regulate
ROS levels by both enhancing their production and reducing
antioxidative/scavenging systems activity [10, 13]. Moreover,
increased ROS levels in turn may increment TGF-𝛽 expres-
sion and stimulate the release of TGF-𝛽 from the secreted
latent complex making this growth factor bioavailable and
active [10, 14].
Both ROS and TGF-𝛽 have important roles in cellular
senescence; ROS can induce cell damage at macromolecular
levels, including damage in nucleic acids, a mechanism
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critical for the development of several age-associated diseases
[15]. In turn, TGF-𝛽 is able to induce senescence in the
early stages of epithelial tumorigenesis [2], partly through
a mechanism implicating ROS production. Tumor cells can
escape senescence by dysregulation in the TGF-𝛽 signaling.
In addition, TGF-𝛽, induced by ROS, may affect cancer-
associated fibroblast by inducing senescence [16] which in
turn collaborates in the enhancement of tumor progression.
Thus, a strong positive feedback between TGF-𝛽 and
oxidative stress/ROS can be established contributing this way
to tumor progression. The aim of this review is to reflect
on TGF-𝛽 as a key molecule in cancer and its molecular
interplay with the oxidative stress produced by ROS, taking
into account that both are involved in the complex cascade of
events that culminate in cancer cell metastasis.
2. Transforming Growth Factor-Beta
TGF-𝛽1 belongs to a large family of more than 40 struc-
turally related regulatory proteins expressed in mammals,
which are organized in several subfamilies: TGF-𝛽s, bone
morphogenetic proteins (BMPs), growth and differentiation
factors (GDFs), Mullerian inhibitory factor (MIF), activins,
and inhibins [17, 18]. Among the TGF-𝛽s, mammals express
three genetically distinct isoforms (TGF-𝛽1, 𝛽2, and 𝛽3) with
high homology. The corresponding human genes are located
on chromosomes 19q13, 1q41, and 14q24, respectively [19]. In
addition to its important role in processes involved in normal
development, which include cell growth and differentiation,
TGF-𝛽 is also involved in tumorigenesis.
TheTGF-𝛽 signaling starts when TGF-𝛽 dimmer binds to
a heteromeric complexmade of two cell surface serine/threo-
nine kinase receptors: TGF-𝛽 type I receptor (T𝛽RI/ALK5,
activin A receptor type II-like kinase 5) and TGF-𝛽 type II
receptor (T𝛽RII). Binding of TGF-𝛽 dimer to T𝛽RII leads to
the phosphorylation and activation of T𝛽RI/ALK5 [20]. The
cytoplasmatic mediators Smad2 and -3 that belong to recep-
tor associated-Smads (R-Smads), a subgroup of Smads, are
then phosphorylated by the activated receptor type I, which
stimulates the release of Smads from the complex formed
with Smad anchor for receptor activation (SARA). Activated
Smad2,3 further bind to the common Smad4 (co-Smad4)
and are translocated into the nucleus. This Smad complex
interacts with several transcription factors, coactivators, or
repressors to regulate the expression of different target genes
(Figure 1) [19, 20].
TGF-𝛽 signaling is regulated by the inhibitory Smad
proteins (I-Smads), Smad6 and Smad7. Principally, Smad7
antagonizes TGF-𝛽 by interacting with T𝛽RI and leading
to its degradation, and Smad6 inhibits the BMP signaling
by Smad1–Smad6 complex formation [21]. On the other
hand, TGF-𝛽 signaling regulates I-Smads expression, thisway
establishing a negative feedback loop. The activity of TGF-𝛽
and its receptors can also be regulated by the type III nonk-
inase receptor (T𝛽RIII) endoglin or betaglycan which are
able to form a complex with other TGF-𝛽 receptors [22]. In
addition, TGF-𝛽/TGF-𝛽 receptor/Smad cascade is subject to
posttranslational modification which finely regulates TGF-𝛽
signaling. These include processes such as phosphoryla-
tion/dephosphorylation, sumoylation, and/or ubiquitination
which reversibly regulate receptor and Smad stability and
availability. Also, ligand-receptor complexes can be inter-
nalized and recycled via lipid rafts/caveolae or clathrin
coated vesicles and lead to TGF-𝛽 protein degradation in the
proteasome, this way attributing to the modulation of
TGF-𝛽 signaling [23]. TGF-𝛽 also activates several non-
Smad pathways such as the mitogen-activated protein kin-
ases (MAPKs), phosphoinositide 3-kinase (PI3K), rac-alpha
serine/threonine-protein kinases (AKT1,2), nuclear factor 𝜅B
(NF-𝜅B), cyclooxygenase-2, and prostaglandins and the small
GTPase proteins: Ras andRho family (Rho, Rac1, andCdc42),
among others (Figure 1) [24, 25].
3. The Role of TGF-𝛽 in Cancer
Depending on the cancer stage, TGF-𝛽 can operate as a tumor
suppressor or as a tumor promoter. Due to its antiprolif-
erative and proapoptotic roles, TGF-𝛽 protects the injured
or stressed epithelium from local mitogenic stimulation in
the early stage of epithelial carcinogenesis. During advanced
stages of carcinogenesis, cancer cells become resistant to the
protective effects of TGF-𝛽 by different mechanisms, includ-
ing modifications in the components of TGF-𝛽 signaling,
such as inactivating mutations in T𝛽RII and Smad4, and
other not fully elucidated alterations [20, 26, 27].
Cancer cells use the capacity of TGF-𝛽 as the most potent
immunosuppressive cytokine, to escape the immune system
surveillance and to induce tumor growth andmetastasis [28].
In order to do so, cancer cells secrete elevated levels of TGF-
𝛽, which acts on nontransformed cells present in tumor
microenvironment, as well as distant cells in the host, this way
suppressing antitumor immune responses and creating an
environment of immune tolerance [29, 30]. In addition, TGF-
𝛽 acts as a chemoattractant for monocytes and macrophages,
which thenmigrate toward the tumor.Macrophagesmodified
in tumormicroenvironment further support tumor invasion,
angiogenesis, and metastasis and also lead to diminished
antigen presentation [31].
The importance of the TGF-𝛽 signaling pathway in
human cancers is evident from the frequent alterations of
TGF-𝛽 signaling components in hereditary human cancers
and sporadic cancers [32]. Several tumors express high levels
of TGF-𝛽, correlating with tumor progression and clinical
prognosis.
Both cancer cells and local stroma produce TGF-𝛽,
which, through autocrine and paracrine effects, induces
cancer growth and its metastatic potential [30]. Elevated
levels of TGF-𝛽 in plasma have been noticed in a number of
cancer types. In breast, prostate, pancreatic, and renal cancer
they have been related to advanced cancer stage, metastases,
and poor clinical outcome [33–35]. In addition, elevated
serum levels of TGF-𝛽 have been observed in myeloma
patients, where both malignant cells and bone marrow stro-
mal cells secrete TGF-𝛽 [36]. TGF-𝛽 levels are also elevated
in non-Hodgkin’s lymphoma and are markedly elevated in
high-grade lymphomas, cutaneous T cell lymphomas with


























Figure 1: TGF-𝛽 signaling. Active TGF-𝛽1 binds to its cell surface type II receptor (T𝛽RII) inducing the activation of TGF-𝛽 type I receptor
(ALK5/T𝛽RI) forming a heterotetrameric complex. Active T𝛽RI from the complex then triggers the activation of the Smad pathway: T𝛽RI
phosphorylates the receptor associated-Smads (R-Smads) Smad2,3 which in turn promotes their release from the complex with SARA from
the inner face of plasmamembrane. Phosphorylated Smads interact with co-Smad4 forming a heteromeric complex to be translocated into the
cell nucleus, where, through the interaction with other transcription factors and corepressors or coactivators, it modulates gene expression.
Active TGF-𝛽-receptors can also activate the non-Smad signaling pathways, such as ERK1,2, p38, JNK, and NF-𝜅B. Furthermore, the active
receptor complex can activate PI3K provoking the activation of AKT and the small Rho GTPases. The activation of non-Smad signaling
pathways can, in turn, initiate transcriptional or nontranscriptional activity to regulate gene and cellular responses.
a T-regulatory phenotype, and splenic marginal zone lym-
phomas presenting as myelofibrosis [30].
Several hereditary cancer syndromes with mutations in
TGF-𝛽 superfamily members are known. The autosomal
dominant familial juvenile polyposis syndrome (JPS) is
the most common of the hamartomatous syndromes [37].
Patients with JPS present multiple hamartomatous polyps
in the gastrointestinal tract, predominantly in the colon, at
a young age, and predispose individuals to gastrointestinal
tract cancers [32]. Germline mutations in different members
of the TGF-𝛽 superfamily have been described in these
patients. In 20–25%of cases BMP receptor type IA ismutated,
the majority in the kinase domain; 15–20% has SMAD4
mutations, predominantly in the MH2 domain. Mutations in
endoglin gene have also been established, but the incidence is
unknown [38, 39].
Homozygous deletion or intragenic inactivating muta-
tions of SMAD4, also named DPC4 for Deleted in Pancreatic
Cancer locus 4, as well as the complete loss of Smad4 protein
expression, are observed in 50% ductal adenocarcinomas,
34% of invasive adenocarcinomas of the Vater ampulla and
55% endocrine pancreatic carcinomas [40]. In addition,
SMAD4 is mutated in 50% of all human pancreatic cancers,
supporting the important tumor suppressor role of the TGF-
𝛽 pathway [41].The autosomal dominant disorder hereditary
nonpolyposis colorectal cancer (HNPCC) is the most com-
mon hereditary predisposition for the development of col-
orectal cancer. HNPCC is caused by germline mutations
involving DNA mismatch repair system genes and con-
tributes tomicrosatellite instability [42]. T𝛽RII gene contains
a 10-base pair polyadenine repeatmicrosatellite sequence and
up to 80% of colon cancer patients with HNPCC present
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mutated forms of T𝛽RII [43]. To summarize, the specific
response to TGF-𝛽 during tumor progression depends on the
stage of carcinogenesis and the responsiveness of the tumor
cells and can be attributed to both independent and inter-
related factors including changes in (1) TGF-𝛽 expression;
(2) TGF-𝛽 receptor expression; (3) availability of downstream
signaling components; (4) evasion of the immune response;
(5) stimulation of inflammation; (6) presence of local and sys-
temic factors (autocrine, endocrine, paracrine, juxtacrine, or
matricrine interactions); and (7) the recruitment of cell types
that lead to advanced tumor growth or promote angiogenesis
[26, 27].
4. Reactive Oxygen Species in Cancer
Reactive Oxygen Species are a family of reactive molecules
which are constantly generated in all aerobic species.
Although ROS levels are balanced by well controlled rate of
generation and elimination or consuming in normal cell con-
ditions, in cancer cells where a dysregulated oxidative stress
may exist, excessive ROS contribute to the chemical damage
of proteins, lipids, and DNA [44] which all may contribute to
tumorigenesis.
Chemically, ROS are small molecules derived from oxy-
gen, comprising free radical and non-free radical oxygen
intermediates, ions, or molecules that have a single unpaired
electron in their outermost shell of electrons and are con-
stantly generated inside cells by enzyme complexes or as
by-products of redox reactions, including those underlying
mitochondrial respiration [45]. ROS include oxygen radicals
(superoxide anion (O2
∙−), hydroxyl (∙OH), peroxyl (RO2
∙),
and alkoxyl (RO∙)) and certain nonradicals that either are
oxidizing agents and/or are easily converted into radicals,
such as hypochlorous acid (HOCl), ozone (O3), singlet oxy-
gen (
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taining oxidants, such as nitric oxide (∙NO) andperoxynitrate
(∙NO
2
) are called reactive nitrogen species (RNS) (revised
in [44] and references therein). The tumor-associated redox
imbalance has been correlated with increased metabolic
activity, mitochondrial dysfunction, deregulated cellular
receptor signaling, peroxisome activity, oncogene activa-
tion, cyclooxygenases (COXes), lipoxygenases (LOXes), and
thymidine phosphorylases, depending on the status of cancer
cells and their cross-talk with stroma and infiltrating immune
cells and enhanced activity ofNADPHoxidase (Nox) [46, 47].
The increased generation of superoxide anion is mostly
accomplished by the Nox/dual oxidase (Duox) family, whose
prototypicalmember is the phagocyticNox (Phox/Nox2) [46,
48]. Five forms of NADPH oxidase have been found: Nox1,
Nox2, Nox3, Nox4, and Nox5 and two forms of dual oxidase:
Duox1 and Duox2. These enzymes are all together now
referred to as the NOX family [49]. The main characteristic
shared by all NOX family members is that they are trans-
membrane proteins transporting electrons across biological
membranes to produce superoxide by reducing oxygen. Nox
family members also possess common conserved structural
properties: (a) NADPH-binding site at the very COOH
terminus; (b) an FAD-binding region in the proximity of
the most COOH-terminal transmembrane domain; (c) six
conserved transmembrane domains; and (d) four highly
conserved heme-binding histidines, two in the third and two
in the fifth transmembrane domain [49]. Importantly, the
small GTPase Rac1 was shown to be a keymolecularmediator
of Nox1, -2, and -3, whereas Nox4, -5 and Doux seem to be
independent of Rac1 [46, 49].
It has been proposed that, in tumorigenesis, ROS pro-
mote several aspects of tumor development and progression
depending on mutagenic potential (initiation); regulation of
intracellular signal pathways involved in the regulation of cell
proliferation and survival; impact on cell motility, invasive-
ness, and metastasis; and cancer cells interplay with tumor
stroma regulating inflammation responses, tissue repair, and
angiogenesis which is vital for tumor growth and dissemina-
tion [47].
5. TGF-𝛽 and ROS Interplay
5.1. ROS Activity Is Regulated by TGF-𝛽. TGF-𝛽 is able to
stimulate ROS production both in transformed and non-
transformed cells [10] and several studies have shown that
TGF-𝛽 can induce ROS production in different cellular com-
partments. TGF-𝛽 induces ROS production in mitochondria
and microsomes in hepatocytes [50, 51], as well as mink lung
epithelial cells by decreasing the activity of complex IV [52].
A mitochondrial thioredoxin (TXN2) sensitive mechanism
which regulates the TGF-𝛽-induced ROS production in
mouse mammary epithelial cells has recently been described.
These data indicate that a cysteine thiol-disulfide exchange
reaction in mitochondria may be involved in TGF-𝛽-medi-
ated regulation of ROS and gene expression [13].





-generating NADH oxidase in human lung fibroblasts
[53]. TGF-𝛽 seems to activate Noxs via Rac1 dependent way
[11]. It activates and/or induces Nox4 in several kinds of cells
in vivo and in vitro [10]. The induction of NOX4 gene
expression by TGF-𝛽 is Smad3 dependent, and this effect is
strongly counteracted by wild type p53 in breast cancer cells
[54, 55]. In addition, TGF-𝛽 was shown to induce NOX4
gene expression along with ROS increase, while the down-
regulation of NOX4 reduced ROS synthesis, indicating that
Nox4 is one of the main sources of ROS in pancreatic cancer
cells [56]. TGF-𝛽 can also induce NOX2 gene expression
and its activation dependent on p40phox subunit (NCF4) in
adenocarcinoma Hela cells [57].
TGF-𝛽 regulates ROS activity, not only by inducing their
production, but also by downregulating the expression of
antioxidant enzymes such as glutaredoxin, catalase, superox-
ide dismutase (SOD), and glutathione peroxidase (GPx) [10].
Moreover, TGF-𝛽 can induce a decrease in concentration of
the important antioxidant glutathione (GSH). One possible
mechanismwhich can explain themechanismbywhichTGF-
𝛽 decreases GSH concentration involves regulated expres-
sion of the GSH catalytic subunit gamma-glutamylcysteine
synthetase (GLC). TGF-𝛽 inhibits the expression of GLC,
this way causing a dramatic reduction in both GLC activity
and GSH levels in the adenocarcinomic human alveolar basal
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epithelial cells A549 [58]. The capacity of TGF-𝛽 to regulate
GLC depends on the transactivation and binding of c-Jun
and Fra-1 complex to AP-1 site in the GLC promoter, as well
as the binding of Smad3 to GLC promoter at the same time
increasing the expression of the transcription factor ATF3,
this way producing a repression of GLC gene expression
[10, 59, 60].These data indicate that TGF-𝛽 is able to increase
ROS levels by downregulating the expression of antioxidant
enzymes concomitantly with the reduction of antioxidant
compounds (Figure 2).
5.2. TGF-𝛽 Signaling Is Regulated by ROS. It is believed that
ROS mediates the TGF-𝛽-regulated expression of a number
of genes, but little is known about how ROS may regulate
the activation of TGF-𝛽 intracellular signal transduction.
As we already mentioned, TGF-𝛽 is able to trigger many
signaling pathways which include Smad and non-Smad
mechanisms. Smad2 signaling seems to be sensitive to ROS
effects, due to studies which showed that TGF-𝛽-stimulated
Smad2 phosphorylation can be inhibited byN-acetyl cysteine
(NAC), reduced glutathione and L-cysteine [61].These results
suggested that thiol groups are important for the suppression
of Smad2 activation and for the prevention of Smad2/Smad4
complexes accumulation in the nucleus [62, 63]. It has





vokes a reduction in T𝛽RII and Smad3 expression which
impairs TGF-𝛽 signaling in human skin fibroblasts [64].
These results are interesting because they show that sustained
ROS levels may act as a negative feedback on TGF-𝛽 signal-
ing, implying the mechanism by which ROS may contribute
to tumorigenesis. In support of our previous statement, some
types of cancers show frequent reduction in T𝛽RII expression
[65].
ROS are able to modulate the TGF-𝛽-mediated acti-
vation of MAPKs by indirect regulation of the activity of
phosphatases which dephosphorylate tyrosine and/or ser-
ine/threonine groups. Protein tyrosine phosphatases such as
PTP1B, serine/threonine phosphatases such as protein phos-
phatase 2A (PP2A), and some dual specific MAPK phos-
phatases (DS-MKPs) such as MKP-1 andMKP-3 can be inac-
tivated by ROS through oxidation of critical cysteine residues
in their active sites, associated with a sustained activation
of MAPK [10, 66]. Additionally, TGF-𝛽 also activates NF-
𝜅B in a ROS dependent way [11], as ROS can influence NF-
𝜅B signaling by potentiating IKK/NEMO dimerization. IKK
complex activation is probably mediated by ROS-sensitive
IKK phosphatases. Activated IKK phosphorylates IKB induc-
ing the release and activation of NF-𝜅B [67]. Intriguingly,
oxidation of NF-𝜅B by ROS inhibits its DNA binding ability
provoking a negative regulation at the nucleus compartment
and inhibition of transcriptional activities of NF-𝜅B [68].
5.3. ROS Activate Latent TGF-𝛽. TGF-𝛽 is firstly synthesized
as an inactive multiprotein precursor complex consisting of
a signal peptide, latency-associated peptide (LAP) domain
and mature TGF-𝛽 (Figure 2). During its transit through
the rough endoplasmic reticulum, the hydrophobic signal
peptide is proteolytically cleaved from the inactive complex
and a dimeric pro-TGF-𝛽 complex is formed. The furin-like
convertase makes the second cleavage, producing the protein
complex consisting of LAP and TGF-𝛽 mature protein. The
noncovalent bonds between these components prevent the
activation of the mature protein, thus creating a small latent
complex (SLC), which passes through the Golgi apparatus.
The SLC binds to a latent 125–160 kDaTGF-𝛽 binding protein
(LTBP) via a disulphide bond giving rise to the large latent
complex (LLC) [69]. Immediately after secretion this complex
is sequestered by the ECM; hence TGF-𝛽 needs to be
activated and released from ECM in order to exert its cellular
effects [14]. The N-terminal region of LTBP is covalently
cross-linked to the ECM by extracellular tissue transglutami-
nase.The hinge domain of LTBP is a protease-sensitive region
and, thus, LLC can be released from the ECM by proteolytic
cleavage. To become bioavailable and capable of binding to its
cell surface receptor, TGF-𝛽 has to be dissociated from LAP
in SLC and/or LLC [14].
Release of TGF-𝛽 from LAP, a process called latent TGF-
𝛽 activation, is required for the binding of TGF-𝛽 to its
receptors [10]. Extracellular activation of the latent TGF-𝛽 is
a complex and important process in the regulation of TGF-𝛽
functions in vivo. The interaction between TGF-𝛽 and LAP
is not covalent and can be disrupted by both proteolytic and
nonproteolytic mechanisms. Physicochemical and biological
variables thatmay participate in the regulation of TGF-𝛽 acti-
vation are heat, local acidification, thrombospondin-1 (TSP1),
integrins, proteinases, and oxidativemodification of LAP due
to its exposure to ROS [69–74].
Barcellos-Hoff and Dix [73] demonstrated that exposure
to ionizing radiation or metal iron plus ascorbate provokes
TGF-𝛽 activation, possibly by oxidative-dependent confor-
mation changes in the latent complex which allow the release
of TGF-𝛽. Similar experiments using asbestos and ascorbic
acid also activated recombinant latent TGF-𝛽, and the partic-
ipation of ROS was demonstrated by addition of superoxide
dismutase, catalase, or deferoxamine which significantly
reduced TGF-𝛽 activation. The activation of latent TGF-𝛽 by
asbestos-ascorbate-mediated generation of ROS apparently
resulted from oxidative modification in LAP, leading to loss
of its ability to bind to TGF-𝛽1 [10, 75]. Although three
isoforms of TGF-𝛽 have been discovered in mammals, only
latent TGF-𝛽1 complex was shown to be sensitive to redox-
mediated activation. Site-specificmutation atmethionine 253
in LAP/TGF-𝛽1 was critical for the latent TGF-𝛽 activation by
ROS, as this amino acid may act as a redox switch allowing
latent TGF-𝛽1 to act uniquely as an extracellular sensor of
oxidative stress in tissues [10, 76]. The response of the TGF-𝛽
sensor to certain types of oxidative stress may reflect a need
for cells to produce TGF-𝛽 during processes such as inflam-
mation and apoptosis that can cause ECM damage through
the production of ROS [14] and may act as protumorigenic
signal in which ROS activation and release of TGF-𝛽 con-
tribute to tumor progression.
Intriguingly, a regulatory loop between oxidative stress/
ROS and TGF-𝛽 can be established in cancer cells. TGF-
𝛽 regulates oxidative stress by both incrementing ROS pro-
duction and regulating the antioxidative system. Meanwhile,





























Figure 2: TGF-𝛽 and ROS interplay. TGF-𝛽 is synthesized as an inactive precursor protein. The signal peptide (SP), which leads the TGF-
𝛽 precursor protein through its secretory pathway, is cleaved during the transit through the rough endoplasmic reticulum (RER), this way
forming a protein homodimer. Its cleavage by furin convertase produces the small latent complex (SLC) in which mature TGF-𝛽 remains
noncovalently bound to latency-associated peptide (LAP). Next, SLC by covalent binding to latent TGF-𝛽 binding protein (LTBP) produces
the large latent complex (LLC). Finally, LLC is secreted and stored in the extracellular matrix for subsequent activation. The increased levels
of ROS induce the release and bioavailability of TGF-𝛽 from the LLC through the oxidative modification of LAP. Active TGF-𝛽 by binding to
its cell surface receptors induces the activation of downstream pathways, which further regulate ROS production by both NOX activation and
increased NOX expression or by downregulation of antioxidative proteins expression. In addition, increased ROS production may directly
induce TGF-𝛽 expression.
ROSmay regulate Smads signaling which contributes to can-
cer cells’ resistance to proliferation inhibition by TGF-𝛽 [77]
in the early stage of tumorigenesis, contrary to the enhance-
ment of MAPK and NF-𝜅B pathways. Moreover, ROS may
regulate TGF-𝛽 expression in epithelial cells [78] and con-
comitantly participate in the activation of latent TGF-𝛽
complex in the ECM, this way incrementing TGF-𝛽 bioavail-
ability. Thus, this ROS-TGF-𝛽 interplay strongly contributes
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to tumorigenesis, avoiding inhibition of cell proliferation and
incrementing cancer cell malignancy. Moreover, TGF-𝛽 is
involved in multiple redox-regulated signaling pathways in
cancer by regulating redox-sensitive transcription factors and
signaling molecules. The increase of ROS may contribute to
increased genomic mutation rates during cancer initiation
[79].Thus, ROS can convert the antitumorigenic role of TGF-
𝛽 in the early stage of tumor progression to a protumorigenic
role and this ROS-TGF-𝛽 interplaymay perpetuate the cancer
phenotype.
6. TGF-𝛽 and ROS in Epithelial
Mesenchymal Transition
EMT is a differentiation process by which epithelial cells
undergo transition to mesenchymal cells. It occurs during
embryogenesis and tissue morphogenesis (type 1 EMT);
wound healing and tissue fibrosis (type 2 EMT); and cancer
progression (type 3 EMT) [27, 80, 81]. Many types of cancer
cells depend on EMT to obtain a migratory phenotype which
enables them to leave primary carcinomas and invade other
tissues [5, 82]. During EMT, early phenotypic changes involve
loss of epithelial cell-cell contacts by downregulation of
junction complex members, which include typical epithelial
markers, claudin-1, ZO-1, and E-cadherin. Interestingly, as E-
cadherin plays a critical role in the epithelial homeostasis,
its downregulation can lead to decreased expression and/or
organization of additional epithelial markers, desmosomal
proteins (such as plakoglobin, desmogleins, and desmo-
plakins) [82, 83]. Furthermore, epithelial cells undergo an
array of modifications during EMT: they lose the apical-basal
polarity showing spindle cell phenotype; their cytoskeleton
is subjected to profound reorganization; the expression of
cytokeratins is lost, along with the expression of mesenchy-
mal vimentin network and rearrangement of actin cytoskele-
ton. Together with an increase of motile behavior, all these
events cooperate to increase tumor cell motility and invasive
cell phenotype [84–86].
Currently, TGF-𝛽 is recognized as a master regulator
of EMT, since it participates in all types of the mentioned
differentiation processes. Tumor cells persistently exposed to
TGF-𝛽 elicit EMT, which plays a pivotal role in cancer pro-
gression [27, 80]. In type 3 EMT, TGF-𝛽may cooperate with
several other oncogenic pathways to induce andmaintain the
mesenchymal phenotype of metastatic tumor cells, allowing
the regulation of TGF-𝛽-induced genes and downregulation
of E-cadherin expression among others [85, 87].
TGF-𝛽 can induce EMT by activating Smad3 signaling,
which, together with Smad4, has been shown to be crucial in
EMT promotion [25, 84, 88, 89]. In contrast to the role of
Smad3, Smad2 has been postulated as an inhibitor of EMT,
since Smad2 ablation enhances EMT during skin carcino-
genesis [90]. Conversely, Smad2 has also been shown to par-
ticipate in the TGF-𝛽1-induced EMT, since overexpression
of constitutively active Smad2 enhances EMT in carcinoma
cells in cooperation with H-Ras oncogene [91]. Considering
disparate results, further analyses are necessary to elucidate
the specific role of Smad2 in EMT. The capacity of TGF-𝛽 to
induce EMT also requires cooperation with a number of dif-
ferent intracellular signaling pathways, such as Ras and Rho
GTPases (Rho and Rac1), MAPKs, Wnts, and NF-𝜅B [11,
92–94]. TGF-𝛽 regulates the expression of EMT-involved
genes by modulating the expression of transcription factors
such as Snail and Slug (corresponding human genes are
named SNAI1 and SNAI2, resp.). For example, Snail mediates
TGF-𝛽-induced EMT by repressing E-cadherin transcrip-
tion and stimulating the expression of mesenchymal genes,
vimentin and 𝛼-SMA, among others. In turn, Snail promotes
collagen-I synthesis and deposition and may upregulate the
expression of proinflammatory interleukins IL-1, -6, and -8
which produce an inflammatorymicroenvironment support-
ing the acquisition of EMT of the cancer cells [85, 95–97].
During EMT cells acquire mesenchymal and stem cell-like
features, increasing their motility and invasiveness, as well
as becoming resistant to apoptosis and acquiring anchorage-
independent growth. Furthermore, upregulation of serine
proteinases such as urokinase plasminogen activator (uPA)
and matrix metalloproteinases (MMPs) leads to the degra-
dation of ECM proteins and provides tumor cells additional
mechanisms to invade surrounding tissues and colonize
distant organs [27, 28, 98, 99].
The influence of ROS on EMT in cancer cells has been
well documented [12]. One mechanism by which ROS can
induce EMT is by its interplay with Snail. ROS can activate
Snail and increased levels of Snail induce intracellular ROS
levels, this way creating a self-regulating loop which leads to
EMT [12, 100, 101]. Hypoxia has also been implicated in ROS-
Snail interaction during EMT, as ROS are not only produced
by aberrant function of mitochondrial complex III during
hypoxic stress but also stabilized by hypoxia inducible factor 1
(HIF-1) [12]. Moreover, HIF-1 induces Snail expression [102]
indicating that hypoxia can provoke a positive scenario for
ROS-Snail interplay in order to enhance EMT in cancer
cells. Interestingly, increased ROS levels cause intercellular
dissociation by provoking a tyrosine phosphorylation of p120
catenin and its cytoplasmic translocation along with intense
cytoskeleton reorganization [103].
Mounting evidence also suggests that TGF-𝛽-induced
EMTmay bemediated by ROS induction [104]. As amultipo-
tent cytokine, TGF-𝛽 also increases the production of extra-
cellular matrix proteinases; cell motility; and invasiveness,
which all together collaborate to enhance tumor progression
[20, 27, 99]. In order to induce EMT, TGF-𝛽 can increase
ROS by two mechanisms: (1) through the inhibition of the
antioxidative capacity of cancer cells and (2) through direct
regulation of ROS production.The inhibition of antioxidative
capacity of cancer cells by TGF-𝛽 is established through the
inhibited expression of antioxidative enzymes. One such
enzyme is cytosolic dithiol glutaredoxin (Grx1) [105], mem-
ber of oxidoreductases thioredoxin superfamily, whichmedi-
ates the reversible electron transfer in reduced/oxidized
glutathione (GSH/GSSG) [106]. It was shown that TGF-𝛽,
in EpRas mouse mammary epithelial cells, downregulated
Grx1 expression and increasedROS levels concomitantlywith
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EMT development.These effects were reverted by exogenous
expression of Grx1 as well as treatment with NAC, suggesting
that the decrease of intracellular antioxidant mechanism
is critical for TGF-𝛽-induced EMT [107]. TGF-𝛽-mediated
EMTwas also inhibited by exogenously expressedmitochon-
drial thioredoxin (TXN2), independently of Smad signaling.
Since TXN2 is antioxidant acting in a particular manner
that facilitates the reduction of disulfide bonds on proteins
by cysteine thiol-disulfide exchange, this implied that thiol
oxidation can be a regulatorymechanism inTGF-𝛽-mediated
gene expression regulation associated with EMT [13]. In
alveolar epithelial cells, the replenishment of intracellular
GSH byNAC treatment was sufficient to block the capacity of
TGF-𝛽 to induce EMT [108]. TGF-𝛽 highly reduces GSH in
these cells, while NAC reduces ROS levels and increases GSH.





induce EMT indicating that oxidative stress is necessary but
not sufficient to induce EMT in these cells. Interestingly, NAC
inhibits Smad3 activation by TGF-𝛽, a pathway important for
TGF-𝛽-stimulated EMT [108].
As previouslymentioned, the capacity of TGF-𝛽 to induce
EMT is also mediated by its capacity to increase ROS pro-
duction. Tobar et al. [11] demonstrated that TGF-𝛽 induces
ROS by a mechanism dependent of Rac1/NOXs in mouse
keratinocytes. ROS can further mediate NF-𝜅B activation
and both collaborate to stimulate EMT induced by TGF-𝛽. In
addition, this effect was parallel with increased cell migration
and extracellular matrix proteinases expression. Further-
more, ROS can induce TGF-𝛽 expression during EMT induc-
tion in human keratinocytes [109], suggesting the possibility
of a TGF-𝛽/ROS/TGF-𝛽 loop operating to induce EMT.
It has recently been reported that TGF-𝛽 increasesNOX4
gene expression by Smad3-dependent mechanism and that
Nox4 contributes to ROS production which may be critical
for the progression of the TGF-𝛽-induced EMT in breast can-
cer and moreover indicates the role of Nox4 in the enhance-
ment of cell motility, without affecting cell proliferation [52].
The role ofNox4has also been confirmed in pancreatic cancer
cells, where blocking ofNox4 impairedTGF-𝛽-inducedEMT.
Also, the Nox4-induced ROS partly regulated the activity of
tyrosine phosphatase-1B (PTP1B), a well-established redox
sensor that can mediate ROS-induced intracellular signaling
[110].
In addition, TGF-𝛽 can induce the expression of
Nox2 during EMT and this activation was dependent on
p40phox subunit (NCF4) which regulates the expression of
other cytosolic regulatory components, including p47phox,
p67phox. Interestingly, NCF4 overexpression was sufficient
to regulate key markers of expression involved in EMT such
as Snail, Slug, and E-cadherin. Moreover, NCF4 seemed to
mediate the transcription/translation regulatory Y-box bind-
ing protein-1 (YB-1) expression by TGF-𝛽. YB-1 is a broad-
specificity RNA-binding protein, mainly involved in the reg-
ulation of mRNA transcription, splicing, translation, and sta-
bility and has recently been implicated in cancer progression
and EMT [57].
The prostate transmembrane protein androgen induced-1
(TMEPAI) has been suggested as a novel mediator affecting
the capacity of ROS to act on TGF-𝛽-induced EMT. TEMPAI
is able to antagonize TGF-𝛽 signaling by interfering with
T𝛽RI/ALK5-induced R-Smads phosphorylation and is over-
expressed in epithelial cancer and highly susceptible to induc-
tion by TGF-𝛽 [111, 112]. Experiments conducted inA549 cells
showed that TMEPAImediates TGF-𝛽-inducedROSproduc-
tion and EMT, as the knockdown of TEMPAI dramatically
reduced ROS concomitantly with decreased EMT. Moreover,
TMEPAI is able to downregulate insulin receptor substrate-1
(IRS-1), an EMT suppressor which plays an important role in
maintaining the epithelial phenotype in cancer cells [113], via
ROS [114]. Clearly, TGF-𝛽 and ROS together participate in
the induction of EMT, as several studies demonstrated that
antioxidant treatments are sufficient to reduce the capacity of
TGF-𝛽 to induce EMT in cancer cells, strongly suggesting the
critical role of oxidative stress in this process. Moreover, ROS
production, dependent or not on TGF-𝛽, may induce TGF-𝛽
expression [10, 78] which may contribute to the development
of EMT by producing a positive ROS-TGF-𝛽 feedback in
cancer cells (Figure 3).
It is believed that EMT acts as a driving force in tumor
progression; it enables cancer cells to invade surrounding
tissues and colonize remote sites. Indeed, EMT represents one
of the main steps in the acquisition of migratory phenotype
of cancer cells and greatly collaborates in the pathogenesis
of cancer [115]. The redox control of EMT emerges as an
important factor which increases tumor malignancy; thus a
prooxidant environment in the tumor, acting on both cancer
and stroma-associated cells, may accelerate tumor progres-
sion [47]. In addition, excess of ROS is deleterious to normal
cells, while the persistent prooxidative state in cancer cells can
lead to intrinsic oxidative stress [79]. Oxidative stress/ROS
may modify cellular response to TGF-𝛽 either by inducing
genetic changes or by regulating cellular behavior, changing
the role of TGF-𝛽 from tumor inhibiting factor to tumor
promoting, and furthermore collaborating with TGF-𝛽 to
lead to EMT in cancer cells with the consequences in tumor
progression. Interestingly, in the tumor microenvironment,
common sources of TGF-𝛽 are cancer and stromal cells, such
as infiltrating immune cells and fibroblast (revised in [116]).
This TGF-𝛽 expression may be regulated by ROS production
within the tumor concomitantly with Smad and non-Smad
signaling pathway modulation, finally leading to EMT [63].
One of the crucial events in cancer disease is the metastasis
formation, which is considered a complex multistep event
with sequential molecular and cellular events including EMT,
migration and invasion, blood vessel intra- and extravasation,
survival, and growth in a new tissue environment [79], in
which the mutual interaction of oxidative stress/ROS and
TGF-𝛽 may play a role in almost all stages described. In
addition, both ROS and TGF-𝛽 also have important roles in
innate immune system response [117], allowing cancer cells
to escape from immune surveillance and incrementing tumor
growth and development, which together with the induction
of EMT strongly cooperate to enhance tumor progression
which is deleterious to cancer patient survival.










Figure 3: TGF-𝛽 and ROS cooperate in the induction of epithelial mesenchymal transition. Both TGF-𝛽 and ROS are involved in the
induction of EMT, aswell as theirmutual cooperation. TGF-𝛽 stimulates ROSproduction in cancer cells, and the enhancement of ROS levels in
turnmay induce the activation of extracellular matrix-associated TGF-𝛽 latent complex, thus exacerbating TGF-𝛽-induced EMT.Meanwhile,
the increment of ROS also stimulates EMT, and both finally may collaborate to induce conversion of the epithelial to the mesenchymal
phenotype, thus strengthening tumor progression and metastasis.
7. ROS and TGF-𝛽 in Cellular
Senescence and Cancer
It is believed that oxidative stress/ROS are important con-
tributors in determining cellular senescence in mammalian
cells [118–120]. Increased levels of ROS may result in macro-
molecular damage (proteins, lipids, and nucleic acids) and are
involved in important mechanisms responsible for cellular
senescence, aging and in the development of several age-
associated diseases [15]. ROS can induce cellular senes-
cence by a telomere-dependent mechanism (revised in [121])
and telomere-independent mechanism [122] involving unre-
pairable single or double-strand DNA breaks. A major DNA
lesion generated by excessive ROS is 8-oxo-2󸀠-deoxyguano-
sine, which is accumulated in senescing human cell cultures
and in ageing mice. The most important effects resulting
from DNA damage are genomic instability and mutations,
which can lead to the development of tumors.Normally,DNA
damage is removed by well functioning repair systems which
prevent harmful cellular changes. However, with increas-
ing age, these systems are more weakened, contributing to
genetic lesions and increased number of cells damaged, with
unfortunate consequences on the development of age-specific
diseases including arthrosclerosis, neurodegenerative dis-
eases, and cancer [123]. Specifically, ROS are known to induce
genomic alterations such as point mutations and deletions
and inhibit tumor suppressor genes as well as induce the
expression of oncogenes. Moreover, ROS may reversibly
regulate intracellular signaling targets such as MAPK, PKC,
PI3K, and phosphatases, resulting in the reorganization of
cytoskeleton, adhesion, and cell migration [119], which col-
laborate in the enhancement of cell malignancy.
Intriguingly, senescence protects damaged cells from
neoplastic transformation by inducing a stable growth arrest,
which is parallel with a secretion of a complex mixture of
factors named as senescence-associated secretory phenotype
(SASP). SAPSmaymediate tumor suppressive effects but also
in another way may exert a protumorigenic role, potentiating
cancer cell malignancy [124].
Essential roles of TGF-𝛽, contributing to its capacity
to suppress early stages of epithelial tumorigenesis, involve
induction of cell arrest, stimulation of apoptosis, and promo-
tion of genomic stability and cellular senescence [2]. It has
been reported in human lung adenocarcinoma cell line that
TGF-𝛽, like ROS, may trigger two independent senescence
programs: one dependent on telomere shortening and second
premature senescence independent of telomere shortening.
When these cells were driven to a senescence state, they
secreted the senescence-associated cytokine IL-6 without
tumorigenic capacities in nude mice, suggesting that TGF-
𝛽-forced induction of senescence in cancer cells can be a
potential anticancer therapy [125].
10 Oxidative Medicine and Cellular Longevity
One of the main mechanisms by which TGF-𝛽 acts as
a negative regulator of cell cycle and as a tumor suppressor
is its capacity to induce cyclin-dependent kinases inhibitors
p15 (ink4b), p16 (ink4a), p21 (Waf/Cip1), and p57. In primary
mouse epidermal keratinocytes engineered to express a viral
Ha-Ras oncogene, which have a high proliferation rate, TGF-
𝛽 strongly induced growth arrest, and senescence associated
with the expression of p16 and p19 (ARF). Expression of
these kinases was dependent on Smad3 signaling. Moreover,
genetic deletion of the cdkn2a (ink4a/arf) locus reduced cell
sensitivity to TGF-𝛽mediated cell cycle arrest and induction
of senescence.This supported the idea that alteration of TGF-
𝛽 molecular and cellular response may be influenced by
cdkn2a locus inactivation during tumor development [77]. It
is believed that the induction of senescence is an attractive
mechanism for the treatments of some types of cancers.
In that way, selected hepatocellular carcinoma (HCC) cells
with intact Smad signaling were highly responsive to TGF-𝛽-
induced cell arrest and senescence both in vitro and in vivo,
with increased expression of p15 (ink4b) and p21 (Waf/Cip1).
In contrast, the inhibition of TGF-𝛽 by T𝛽RII deletion abol-
ished in vitro senescence response and greatly accelerated in
vivo tumor growth. Interestingly, the induction of senescence
was also associated with the TGF-𝛽-mediated induction of
Nox4 expression and ROS production.The reduction of ROS
by using NAC or Nox4 siRNA inhibited TGF-𝛽-induced
senescence and accumulation of p15 and p21 [126]. It has
also been suggested that TGF-𝛽 may participate in oxidative
stress-induced senescence by regulating the expression of
adenine nucleotide translocase-2 (ANT2). ANT2 is consis-
tently downregulated during the course of all major types
of cellular senescence including replicative, oncogene- and
radiation/drug-induced forms in normal human diploid
fibroblasts. TGF-𝛽, by inducing formation of NF1/Smad4
complex, inhibits ANT2 in cancer cells, and this repression of
ANT2 contributes to senescence-associated oxidative stress
and DNA damage [127].
Asmentioned previously, several cancers showed reduced
response to TGF-𝛽 by presenting abnormalities in TGF-𝛽
receptors or Smad4, a mechanism by which cancer cells may
escape fromTGF-𝛽-induced senescence. In viral Ha-Ras ker-
atinocytes TGF-𝛽-null and dominant negative T𝛽RII trans-
fected cells are highly resistant to cell cycle arrest and senes-
cence. These cells show low expression of p15 (ink4b) and
p16 (ink4a) and high levels of cdk4 and cdk2 activity. There-
fore, inactivation of TGF-𝛽1 expression or its response seems
to be sufficient to overcome the senescence program and
accelerate malignant progression [128]. Similarly, the expres-
sion of a dominant-negative T𝛽RII abrogated autocrine TGF-
𝛽 signaling in telomerase-immortalized HMECs and sup-
pressed H-Ras-V12-induced senescence-like growth arrest
[129].
It has been suggested that cancer cells can also induce a
form of “accelerated aging” in cancer-associated fibroblasts,
via ROS production and oxidative stress. This in turn may
provide a more supportive microenvironment to tumor cells
growth [130]. In this aspect, it has recently been reported
that, in genetically unstable oral squamous cell carcinomas
(GU-OSCC), fibroblasts are displaying senescent phenotype.
The increased levels of ROS in tumors induced fibroblast-
dependentTGF-𝛽production, and this factor inducedfibrob-
last senescence. Moreover, senescent fibroblasts show high
capacity to stimulate malignant keratinocytes invasion in
vitro. This study demonstrated that, in GU-OSCC, the senes-
cent cancer-associated fibroblasts, maintained by ROS and
TGF-𝛽 induced by cancer cells, promote tumor malignancy
[16].
8. Concluding Remarks
A large number of evidence in the literature confirms the
important role of TGF-𝛽 and ROS in the course of cancer
progression andmetastasis. Due to its importance in tumori-
genesis, TGF-𝛽 and oxidative stress/ROS system is a very
attractive target in cancer chemotherapy.
Targeting TGF-𝛽 has already been clinically tested in
therapeutic approaches. These strategies included small
inhibitors of the enzymatic activity of uPA or TGF-𝛽 recep-
tors, specific neutralizing antibodies, peptide inhibitors such
as p44, and therapeutic approaches to control the expression
of TGF-𝛽 signaling components at transcriptional level,
among others [17]. Currently, most clinical trials have failed
to showbeneficial effects of dietary antioxidants in a variety of
cancer types [9, 131]. ROS can have contrary roles in tumori-
genesis, as they can trigger aberrant procancer signaling and
DNA mutations, whereas high levels of ROS can be toxic
to cancer cells, this way affecting their survival. Thus, ROS
status seems to be a critical aspect in the balance between
cancer cell survival and their advance to more malignant
stages and tumor suppression and cell death, which can easily
be disrupted in favor of each side. In one way, cancer cells, by
increasing their antioxidant capacity, may balance oxidative
stress status, suggesting that prooxidant approaches may be
exploited in cancer therapy. Some evidence are indicating that
dietary antioxidants contribute to tumorigenesis, probably by
protecting cancer cells from ROS-induced cell death [132].
One of the most fascinating aspects of cancer cells is their
capacity to adapt and reprogram their homeostasis to onco-
gene mutations, changes in metabolism, extreme changes in
microenvironment (including hypoxia and acidic changes),
taking advantage of these stressors to survive and increase cell
malignance [9]. In fact, ROS in more advanced tumor stages
may collaborate with growth factors (TGF-𝛽) to increase cell
survival,migration and invasion, and finallymetastasis.Thus,
cancer cells can balance prooxidant and antioxidant activities,
in a well orchestrated regulation, by taking advantage from
the changes in ROS homeostasis in order to survive and to
progress in tumorigenesis.
In this review, we attempted to reveal the interplay
between TGF-𝛽 and ROS. We believe that the inhibition or
regulation of the amplification loop operated between TGF-𝛽
and ROS system in tumor cells could limit tumor progression
and metastasis, impairing tumor dissemination, prolifera-
tion, and survival. We hope future clinical trials using com-
bined therapies which target TGF-𝛽 and oxidative stress/ROS
could increase the success of cancer treatment. Moreover,
TGF-𝛽 and ROS induce EMT, which enhances tumor cells
migration and invasion. In addition, TGF-𝛽 and ROS are
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both implicated in cellular senescence, which can be a useful
therapy target in the early stages of tumor progression. This
also opens the question about the use of antioxidants in
oncotherapies, since they may delay epithelial cancer cells
senescence dependent on the ROS increment. However, the
use of antioxidants in combinationwith current clinical treat-
ments should be carefully considered, since antioxidants can
determine the senescence of fibroblasts in tumor stroma, this
way enhancing tumorigenesis. By regulating TGF-𝛽 and
oxidative stress/ROS it could be possible to control the
positive tumor microenvironment and cancer-stroma cells
interactions.
Finally, elucidating the complex interplay and roles of
TGF-𝛽 and oxidative stress in cancer is critical for the under-
standing of their participation in the initiation, progression,
and tumormetastasis and could eventually uncover potential
combinatory therapeutics for future cancer treatment in
humans.
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